

## Nomination Committee of Medivir appointed

**Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2025.**

According to an AGM resolution, the Nomination Committee 2024-2025 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2024 and the Chairman of the Board.

Work on composing the Nomination Committee is now completed, and this year's Nomination Committee consists of:

**Karl Tobieson**, appointed by Linc AB

**Richard Torgerson**, appointed by Nordea Funds AB

**Anders Hallberg**, appointed by Hallberg Management AB

**Uli Hacksell**, Chairman of the Board, Medivir AB

The 2025 Annual General Meeting of Medivir will be held on Wednesday May 7, 2025.

**For additional information, please contact;**

Magnus Christensen, CFO, Medivir AB

Telephone: +46 8 5468 3100

E-mail: [magnus.christensen@medivir.com](mailto:magnus.christensen@medivir.com)

**About Medivir**

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacinibine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. [www.medivir.com](http://www.medivir.com).